AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4020675
Drug: Lorazepam with
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam with probenecid (500 mg every 6 hr)
Trial: 23455717
Drug: FLOT (biweekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT (biweekly oxaliplatin plus 5‐fluorouracil continuous infusion and folinic acid plus docetaxel 50 mg/m²)
Trial: 23455717
Drug: FLO (biweekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLO (biweekly oxaliplatin plus 5‐fluorouracil continuous infusion and folinic acid)
Trial: 23327127
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (diazepam 0.2 mg/kg)
Trial: 23327127
Drug: Group K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group K (ketamine 5% 30 mg/kg)
Trial: 23327127
Drug: Group KD
RxNorm normalized name: polyquaternium-7 (76-24 acrylamide-dadmac; 120 kD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group KD (ketamine 5% 10 mg/kg + diazepam 0.2 mg/kg)
Trial: 20512109
Drug: No desensitising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No desensitising agent (Group B)
Trial: 12641628
Drug: High-dose adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adjuvant I-131 therapy
Trial: 10347109
Drug: Midodrine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine and octreotide with 20% human albumin solution (50 to 100 mL daily for 20 days)
Trial: 10347109
Drug: Dopamine (2‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (2‐4 micrograms/kg/min) with the same daily amount of albumin
Trial: 30408271
Drug: Attention Bias
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Bias Modification (ABM) therapy
Trial: 22329987
Drug: Short-term energy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term energy surfeit treatment (BOOST®)
Trial: 15939317
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 mcg
Trial: 15939317
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 mcg
Trial: 1660825
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of conjugated oestrogen, dosage not specified, duration not specified.
Trial: 1660825
Drug: Atropine sulphate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine sulphate, dosage not specified, duration not specified.
Trial: 7041323
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG (0.4 to 0.9 X 10(6) viable units)
Trial: 752875
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BCG immunotherapy)
Trial: 15855885
Drug: Daily alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily alcohol intake
Trial: 8905028
Drug: Three-weekly chemotherapy
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Trial: 8905028
Drug: Four-weekly chemotherapy
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Trial: 1756257
Drug: pT2 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pT2 and G-II carcinomas
Trial: 6802691
Drug: Hydrochlorothiazide (HCZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCZ) 50 mg once daily (or 50 mg twice a day for 2 patients)
Trial: 6802691
Drug: Hydrochlorothiazide (HCZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCZ) plus Nadolol (40 mg to 240 mg once daily)
Trial: 6802691
Drug: Nadolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (40 mg to 240 mg once daily)
Trial: 29562396
Drug: Radiofrequency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency treatment with ultrasound guidance
Trial: 24221577
Drug: Irradiated organic
RxNorm normalized name: Organix Complete
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiated organic manuka honey (5 ml, four times a day during radiation treatment plus seven days)
Trial: 24221577
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (5 ml, four times a day during radiation treatment plus seven days)
Trial: 22819187
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 1 (n = 39)
Trial: 22819187
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 4 (n = 41)
Trial: 11985944
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.35 g/kg of fat-free mass)
Trial: 8536758
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and cisplatin (135 mg/m2 or 175 mg/m2 of paclitaxel and 50 mg/m2, 75 mg/m2, or 100 mg/m2 of cisplatin)
Trial: 25592751
Drug: 14.5 g
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 214.5 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14.5 g spices (black pepper, cinnamon, cloves, garlic, ginger, oregano, paprika, rosemary, and turmeric)
Trial: 24151277
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) administration (35 mg once weekly for six months)
Trial: 24151277
Drug: Delayed ALN
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed ALN administration (not specified dosage, started four months after surgery)
Trial: 11527909
Drug: 0.5% ferric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ferric hyaluronate gel
Trial: 9428861
Drug: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3) intravenous bolus dose of 240 mg followed by continuous infusion at 90 mg/h for 24 h
Trial: 7641722
Drug: ketamine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 1.5 mg kg‐1
Trial: 2621178
Drug: Acyclovir, 800
RxNorm normalized name: Acyclovir, 800 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 800 mg tid
Trial: 1251139
Drug: Prophylaxis replacement
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis replacement therapy with biweekly administration of 7.5 U/kg of factor IX concentrate
Trial: 1251139
Drug: Prophylaxis replacement
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis replacement therapy with weekly administration of 15 U/kg of factor IX concentrate
Trial: 1251139
Drug: Prophylaxis replacement
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis replacement therapy (both schemes)
Trial: 31448433
Drug: Upadacitinib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib (1 mg to 48 mg)
Trial: 31448433
Drug: Tofacitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5 mg BID)
Trial: 31448433
Drug: Upadacitinib (∼12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib (∼12 mg BID)
Trial: 31221115
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation (Pre-CRT) - two cycles of S-1 and oxaliplatin (SOX), followed by chemoradiation, then surgery and three more cycles of SOX chemotherapy.
Trial: 31221115
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (Pre-CT) - three cycles of SOX, followed by surgery and three more cycles of SOX chemotherapy.
Trial: 28646390
Drug: Laser +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser + topical drug (calcipotriol ointment)
Trial: 28646390
Drug: Drug alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug alone (calcipotriol ointment)
Trial: 21640878
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B mouthwash
Trial: 21640878
Drug: All mouthwashes
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All mouthwashes (Chlorhexidine, Oral B, Persica)
Trial: 16769002
Drug: 3-S saphenectomy
RxNorm normalized name: (S)-3-Isobutyl GABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-S saphenectomy technique (sclerosis injection at the sapheno-femoral junction with microfoam through a catheter, with saphenectomy and distal phlebectomies)
Trial: 12685950
Drug: Hyoscinbutylbromide in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscinbutylbromide in infusion
Trial: 1753422
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of norfloxacin (chemoprophylaxis)
Trial: 1753422
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (without any antimicrobials except when overt UTI occurred)
Trial: 6760378
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of azathioprine
Trial: 6760378
Drug: 10-15 mg
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 mg of prednisone daily
Trial: 3882107
Drug: Intravenous BRL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous BRL 26921
Trial: 15712339
Drug: Uncertainty management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncertainty management intervention delivered during four weekly telephone sessions with cognitive-behavioral strategies and a self-help manual.
Trial: 1685665
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 50 mg remoxipride
Trial: 1685665
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 100 mg remoxipride
Trial: 1685665
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release capsules (A and B) of 100 mg remoxipride
Trial: 31680269
Drug: Routine blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine blood glucose assessment at intervention hospitals; automatic requests for glycated haemoglobin (HbA1c) assessment and notification of diabetes services about patients with blood glucose levels of 14 mmol/L or more.
Trial: 19916254
Drug: Ultrasound-guided supraclavicular
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided supraclavicular brachial plexus block with 20 mL of 0.75% ropivacaine
Trial: 19916254
Drug: Nerve stimulation
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulation supraclavicular brachus plexus block with 20 mL of 0.75% ropivacaine
Trial: 12862299
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (5 mg/kg as a 30 min infusion, followed by 10 mg/kg during 20 hours in GIKM solution)
Trial: 12862299
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1000 ml of GIKM alone)
Trial: 8523058
Drug: Fluorouracil plus
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plus levamisole (450 mg/m2 IV daily for 5 days, then weekly for 48 weeks; levamisole 50 mg orally three times daily for 3 days every 2 weeks for 1 year)
Trial: 30272088
Drug: 5-year multifactorial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-year multifactorial intervention consisting of personal health education and contemporary drug treatments for dyslipidemia and hypertension.
Trial: 3438580
Drug: Usual medical
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medical treatment
Trial: 22622008
Drug: Chemoradiotherapy (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (60 Gy plus concurrent low-dose carboplatin [30 mg/m² per day, 5 days a week for 20 days])
Trial: 16134756
Drug: Valsartan (20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (20-80 mg per day)
Trial: 7808837
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) treatment, 0.5 mg/kg/d for 1 week
Trial: 11570643
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) treatment
Trial: 30985667
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with PapacarieMBlue
Trial: 28398846
Drug: TaxAC (docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TaxAC (docetaxel, doxorubicin, and cyclophosphamide or other standard AC and taxane combination regimens)
Trial: 24095299
Drug: Etirinotecan pegol
RxNorm normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etirinotecan pegol 145 mg/m(2) every 14 days
Trial: 24095299
Drug: Etirinotecan pegol
RxNorm normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etirinotecan pegol 145 mg/m(2) every 21 days
Trial: 20807262
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of caffeine and sulfo-carrabiose
Trial: 16913238
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose administration
Trial: 26906165
Drug: RTH258 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTH258 4.5 mg
Trial: 26906165
Drug: RTH258 6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTH258 6.0 mg
Trial: 31750396
Drug: ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranibizumab 0.5 mg
Trial: 21609286
Drug: Leucine-protein, high-carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine-protein, high-carbohydrate nutrition (0.1/0.4/1.2/0.2 g·kg(‐1)·h(‐1))
Trial: 21609286
Drug: Isocaloric control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric control (0.06/1.6/0.2 g·kg(‐1)·h(‐1))
Trial: 16697231
Drug: Oral Lactobacillus
RxNorm normalized name: Lactobacillus acidophilus Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Lactobacillus rhamnosus GR‐1 (1 x 10(9)) and Lactobacillus reuteri RC‐14 (1 x 10(9))
Trial: 8024295
Drug: Budesonide via
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide via Turbuhaler (half the normal dose)
Trial: 8024295
Drug: Budesonide via
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide via Nebuhaler (normal dose)
Trial: 3501538
Drug: 5-fluorouracil (FUra)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (FUra) plus high-dose continuous-infusion folinic acid
Trial: 31255546
Drug: Implant position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant position
Trial: 31255546
Drug: Implant material
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant material
Trial: 29128208
Drug: Whole pelvic
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole pelvic radiation therapy (WPRT)
Trial: 29128208
Drug: Prostate bed
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate bed radiation therapy (PBRT)
Trial: 29128208
Drug: No androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No androgen deprivation therapy (No ADT)
Trial: 18663341
Drug: Protection cream
RxNorm normalized name: PETROLATUM 300 mg in 1 mL TOPICAL CREAM [CUREFINI Skin Protection Cream]
DrugBank: Titanium dioxide (DB09536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protection cream containing antioxidant substances with high radical protection factor
Trial: 14511552
Drug: Severe malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe malaria requiring intravenous quinine therapy
Trial: 8648387
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy alone
Trial: 8648387
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy with mantle or mediastinal RT
Trial: 2428795
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy
Trial: 29282600
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 28971727
Drug: DSL prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSL prescription
Trial: 28971727
Drug: NAL prescription
RxNorm normalized name: Foster & Thrive All Day Allergy Original Prescription Strength 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAL prescription
Trial: 28971727
Drug: Both DSL
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both DSL and NAL prescriptions
Trial: 27496577
Drug: Arthrocentesis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis and BTX‐A injections in the temporal and masseter muscles (Group A)
Trial: 27496577
Drug: BTX‐A injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX‐A injections in the temporal and masseter muscles only (Group B)
Trial: 18505783
Drug: Oral melphalan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melphalan, prednisone, and thalidomide (MPT)
Trial: 10537443
Drug: Lamivudine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (150 mg twice daily)
Trial: 10537443
Drug: Lamivudine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (150 mg twice daily) plus Loviride (100 mg 3 times daily)
Trial: 2054076
Drug: GORE-TEX bags
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GORE-TEX bags containing silver sulphadiazine cream
Trial: 27410169
Drug: Vacuum‐formed co‐polyester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum‐formed co‐polyester oral splints (Group B)
Trial: 27410169
Drug: Prefabricated oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefabricated oral splints with water‐filled elastic pads (Group A)
Trial: 19860749
Drug: Levobupivacaine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 20 mg (5 mg/ml)
Trial: 19860749
Drug: Lidocaine 80
RxNorm normalized name: LIDOCAINE 80 mg TOPICAL RING [LidoBand]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 80 mg (20 mg/ml)
Trial: 12384409
Drug: Chronic GVHD
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic GVHD treatment
Trial: 31064236
Drug: Topical Platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Platelet-rich plasma (PRP) applied twice a day for 12 weeks
Trial: 31064236
Drug: Gentamicin and
RxNorm normalized name: Gentamicin and prednisolone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin and betamethasone for the first 7 days, then hyaluronic acid gel for 12 weeks
Trial: 26704712
Drug: Proanthocyanidin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proanthocyanidin (200 mg)
Trial: 26704712
Drug: Control (starch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (starch, 200 mg)
Trial: 25010702
Drug: Psychosocial Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial Treatment as Usual (TAU)